title: Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
abstract: OBJECTIVE
  What are the benefits and harms of iron supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with ESA alone in the treatment of chemotherapy-induced anemia?
  
  
  CONCLUSIONS
  Addition of iron to ESAs improves hematopoietic response, reduces the need for red blood cell transfusions, increases hemoglobin levels, and seems to be well tolerated. The subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the treatment of chemotherapy-induced anemia.
authors.affiliation: Program for Comparative Effectiveness Research and Evidence Based Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida.
authors.forename: Rahul
authors.initials: R
authors.lastname: Mhaskar
authors.affiliation: Program for Comparative Effectiveness Research and Evidence Based Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida2H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida3Department of Medicine, Tampa General Hospital, Tampa, Florida.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Djulbegovic
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019587:Dietary Supplements; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D060828:Induction Chemotherapy; D007501:Iron; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D004921:Erythropoietin; D007501:Iron